Tonix's TONMYA improves fibromyalgia symptoms, physical function in Phase 3 studies

• Tonix Pharmaceuticals presented Phase 3 TONMYA findings at the IASP World Congress on Pain in Bangkok on Oct. 27, 2026.
• The RELIEF and RESILIENT trials showed improved physical symptoms, daily functioning and pain versus placebo in adults with fibromyalgia.
• TONMYA was generally well tolerated, with no new safety signals; local oral reactions were the most common treatment-emergent adverse events.
• Commercial sales began in November 2025 following FDA approval on Aug. 15, 2025, the first new fibromyalgia medicine in over 15 years.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tonix Pharmaceuticals Holding Corp. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610270700PRIMZONEFULLFEED9853730) on October 27, 2026, and is solely responsible for the information contained therein.